FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib

被引：0
|
作者：
Lixia Gao
Xuli Wang
Yaoliang Tang
Shuang Huang
Chien-An Andy Hu
Yong Teng
机构：
[1] Augusta University,Department of Oral Biology, Dental College of Georgia
[2] University of Utah,Department of Radiology and Imaging Sciences, School of Medicine
[3] University of Utah,Experimental Therapeutics Program, Huntsman Cancer Institute
[4] Augusta University,Vascular Biology Center, Department of Medicine, Medical College of Georgia
[5] University of Florida College of Medicine,Department of Anatomy and Cell Biology
[6] University of New Mexico School of Medicine,Department of Biochemistry and Molecular Biology
[7] Augusta University,Department of Biochemistry and Molecular Biology, Medical College of Georgia
来源：
Journal of Experimental & Clinical Cancer Research | / 36卷
关键词：
FGF19; FGFR4; Hepatocellular carcinoma; Drug resistance; Sorafenib; Synergistic effect;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Targeting FGF19 as a therapeutic for hepatocellular carcinoma
    Hotzel, K. H.
    Pai, R. P.
    Ferrando, R. F.
    Rodriguez, L. R.
    Le, T. L.
    Greve, J. G.
    Desnoyers, L. D.
    Ashkenazi, A. A.
    French, D. F.
    EJC SUPPLEMENTS, 2007, 5 (04): : 65 - 65
  • [32] Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104
    Li, Fan
    Li, Ziming
    Han, Qing
    Cheng, Yirui
    Ji, Wenxiang
    Yang, Ying
    Lu, Shun
    Xia, Weiliang
    ONCOGENE, 2020, 39 (17) : 3507 - 3521
  • [33] Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104
    Fan Li
    Ziming Li
    Qing Han
    Yirui Cheng
    Wenxiang Ji
    Ying Yang
    Shun Lu
    Weiliang Xia
    Oncogene, 2020, 39 : 3507 - 3521
  • [34] Exploring the involvement of FGFR4 in hepatocellular carcinoma
    Ho, Han Kiat
    Pok, Sharon
    Ruhe, Jens E.
    Hart, Stefan
    Streit, Sylvia S.
    Loo, Hooi Linn
    Foo, Priscilla
    Do Aung, Myat
    Ullrich, Axel
    Lim, Seng Gee
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3549S - 3550S
  • [35] miR-486-3p mediates sorafenib resistance through targeting FGFR4 and EGFR in hepatocellular carcinoma
    Ji, Lin
    Lin, Zhongjie
    Wan, Zhe
    Xia, Shunjie
    Jiang, Shi
    Cen, Dong
    Cai, Liuxin
    Xu, Junjie
    Cai, Xiujun
    JOURNAL OF HEPATOLOGY, 2020, 73 : S901 - S901
  • [36] Src is essential for the endosomal delivery of the FGFR4 signaling complex in hepatocellular carcinoma
    Ji-Yon Shin
    Sung-Min Ahn
    Journal of Translational Medicine, 19
  • [37] Src is essential for the endosomal delivery of the FGFR4 signaling complex in hepatocellular carcinoma
    Shin, Ji-Yon
    Ahn, Sung-Min
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [38] Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice
    Wu, Xinle
    Ge, Hongfei
    Lemon, Bryan
    Weiszmann, Jennifer
    Gupte, Jamila
    Hawkins, Nessa
    Li, Xiaofan
    Tang, Jie
    Lindberg, Richard
    Li, Yang
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (34) : 14379 - 14384
  • [39] Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma
    Tai, David Wai Meng
    Le, Thi Bich Uyen
    Prawira, Aldo
    Ho, Rebecca Zhi Wen
    Huynh, Hung
    HEPATOLOGY INTERNATIONAL, 2021, 15 (05) : 1236 - 1246
  • [40] Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma
    David Wai Meng Tai
    Thi Bich Uyen Le
    Aldo Prawira
    Rebecca Zhi Wen Ho
    Hung Huynh
    Hepatology International, 2021, 15 : 1236 - 1246
12345